Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics, Inc. reported that Chief Medical Officer Terence Rooney received equity awards consisting of 76,000 stock options to buy common stock at $110.05 per share, expiring July 26, 2036, plus 38,000 restricted stock units. The RSUs vest in four equal annual installments following July 27, 2026, and the options vest 25% on July 27, 2027 with the remainder in 36 equal monthly installments, in each case subject to his continued employment.
Kymera Therapeutics, Inc. filed an initial statement of beneficial ownership on Form 3 for Rooney Terence, who serves as Chief Medical Officer. This establishes him as a reporting officer under SEC rules and references an Exhibit 24 Power of Attorney relating to SEC filing authorizations.
Kymera Therapeutics, Inc. announced a leadership transition in its Chief Medical Officer role. Jared Gollob, M.D., submitted his resignation as CMO on July 27, 2026, citing personal reasons and indicating it was not due to any disagreement with the company’s practices or policies. He will continue serving as an advisor through December 31, 2026.
Effective July 27, 2026, Terence Rooney, M.D., a veteran immunology drug development leader with experience at Johnson & Johnson, Eli Lilly and Roche, becomes CMO and will lead global clinical development strategy for Kymera’s oral immunology portfolio. The company furnished a press release as Exhibit 99.1 describing his background and Dr. Gollob’s eight years of leadership.
Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale. He exercised stock options to acquire 50,000 shares of Common Stock at an exercise price of $2.08 per share, then sold 50,000 Common shares at an average price of $119.00 per share.
Following these transactions, he directly owned 666,568 Common shares. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and the options involved were fully vested and exercisable.
Nello Mainolfi files a Form 144 notifying a proposed sale of 50,000 shares via exercise of stock options. The filing states the transaction is an exercise of stock options to be effected on 07/07/2026 for cash. It also discloses a prior sale of 80,000 shares on 07/01/2026 for $9,223,529.00.
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of stock option exercises and share sales in Kymera Therapeutics, Inc. common stock. On June 30, 2026, he exercised options to acquire 61,378 shares at an exercise price of $5.33 per share and then sold 77,109 shares in open-market transactions. The sales occurred in multiple trades at weighted average prices within ranges from $110.37 to $118.09 per share, as detailed in the price footnotes. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 23, 2026, indicating they were scheduled in advance. Following the transactions, Jacobs directly holds 244,883 shares of Kymera common stock.
Kymera Therapeutics Chief Business Officer Noah Goodman sold 3,389 shares of common stock in an open-market transaction at $114.29 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the sale, Goodman directly holds 47,179.438 shares, which includes 373 shares acquired through Kymera’s employee stock purchase plan.
Kymera Therapeutics CEO Nello Mainolfi reported a mix of option exercises and share sales in the company’s stock. On July 1, 2026, he exercised stock options for 80,000 shares of common stock at an exercise price of $2.08 per share, converting a derivative position into regular shares.
That same day, he sold 80,000 shares of common stock in five open-market transactions at weighted average prices ranging from about $112.28 to $116.63 per share. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and notes that he continues to hold a substantial direct equity stake in Kymera.
Kymera Therapeutics director-related entities reported an amended open-market sale of Kymera common stock. Entities associated with Bruce Booth, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a total of 76,650 shares of Kymera Therapeutics, Inc. on June 29, 2026.
The trades were executed as open-market sales at weighted average prices within ranges from about $105.02 to $111.63 per share under a Rule 10b5-1 trading plan adopted on December 11, 2025. The filing is an amendment that corrects previously misreported numbers of shares disposed and owned following the transactions. Booth reports these holdings indirectly through the Atlas funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
KYR Medicines, Inc. (KYMR) reported a Section 144 notice indicating an intended sale of 80,000 shares of Common Stock on 07/01/2026 arising from an exercise of stock options with cash as the payment method. The filing also records a prior sale of 30,000 shares on 04/29/2026.
The filing lists an aggregate dollar figure of $9,143,200.00 and a share count of 82,257,588 tied to 07/01/2026. The notice names Nello Mainolfi in the recent sale record.